Skip to main content
SK Bioscience Co.,Ltd logo

SK Bioscience Co.,Ltd — Investor Relations & Filings

Ticker · 302440 ISIN · KR7302440003 KO Manufacturing
Open in API
Filings indexed 383 across all filing types
Latest filing 2022-04-28 Director's Dealing
Country KR South Korea
Listing KO 302440

About SK Bioscience Co.,Ltd

https://www.skbioscience.com/

SK Bioscience is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of vaccines and biological products. Spun off from SK Chemicals in 2018, the company develops its own pipeline of vaccines, including cell-culture-based influenza vaccines and a COVID-19 vaccine, utilizing its established R&D and production platforms. In addition to its proprietary products, SK Bioscience provides global Contract Development and Manufacturing Organization (CDMO) services, offering end-to-end support from process development to large-scale commercial manufacturing for international partners. The company is dedicated to promoting public health by providing innovative preventative solutions to address global health challenges.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service in South Korea. This type of filing is specifically used to disclose insider transactions, such as the sale or transfer of shares by company executives. Based on the provided definitions, this corresponds to 'Director's Dealing' (DIRS).
2022-04-28 Korean
[기재정정]투자판단관련주요경영사항(COVID-19 백신 GBP510의 제3상 임상시험 결과 발표)
Regulatory Filings Classification · 1% confidence The document is a regulatory filing from SK Bioscience regarding the results of a Phase 3 clinical trial for their COVID-19 vaccine (GBP510). It is structured as a 'Major Management Matter' (투자판단 관련 주요경영사항) filing, which is a standard regulatory disclosure format in the Korean market (KRX) for material corporate events. Since it does not fit into specific categories like financial reports, board changes, or dividend announcements, and serves as a formal regulatory disclosure of material information, it is classified as a Regulatory Filing (RNS).
2022-04-28 Korean
투자판단관련주요경영사항(COVID-19 백신 GBP510의 제3상 임상시험 결과 발표)
Regulatory Filings Classification · 1% confidence The document is a regulatory filing from SK Bioscience regarding the results of a Phase 3 clinical trial for a COVID-19 vaccine (GBP510). It is structured as a 'Major Management Matter' (투자판단 관련 주요경영사항) filing, which is a standard regulatory disclosure format in the Korean stock market (KRX) for material events. Since it reports specific clinical trial outcomes rather than a general report publication announcement, and does not fit into specific categories like M&A or financial results, it is classified as a general regulatory filing.
2022-04-25 Korean
최대주주등소유주식변동신고서
Director's Dealing Classification · 1% confidence The document is a 'Report of Change in Shareholding by Major Shareholders and Others' (최대주주등소유주식변동신고서) for SK Bioscience. It details specific transactions (sales) of shares by company executives (directors/officers). According to the filing definitions, reports of personal share transactions by company directors and executives are classified as 'Director's Dealing' (DIRS).
2022-04-21 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities. It details the sale of shares by an executive (Jeon Kwang-hyun) of SK Bioscience. This type of filing, which reports personal share transactions by company directors and executives, is classified as 'Director's Dealing'.
2022-04-21 Korean
투자판단관련주요경영사항(COVID-19 백신 GBP510의 부스터샷 제3상 임상시험계획(IND) 승인)
Regulatory Filings Classification · 1% confidence The document is a regulatory filing from SK Bioscience regarding the approval of a Phase 3 clinical trial for a COVID-19 vaccine booster (GBP510). It follows the standard format for 'Major Management Matters' (투자판단 관련 주요경영사항) required by the Korea Exchange (KRX). Since it is a specific regulatory disclosure regarding clinical trial status and does not fit into categories like financial reports, dividends, or M&A, it is classified as a general regulatory filing.
2022-04-21 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.